<DOC>
	<DOCNO>NCT01576640</DOCNO>
	<brief_summary>After successfully quit smoking , smoker schizophrenia vulnerable relapse shortly discontinuation treatment . The purpose study assess feasibility effectiveness 12-month relapse prevention intervention recently abstinent smoker schizophrenia . Subjects participate 12-week smoking cessation phase , receive nicotine replacement therapy , bupropion SR 150mg bid , cognitive behavioral therapy . If , end 12 week , able demonstrate 1 week abstinence , continue relapse prevention phase study , continue receive nicotine replacement therapy , bupropion SR 150mg bid , cognitive behavioral therapy .</brief_summary>
	<brief_title>Extended Duration Nicotine Replacement Therapy Bupropion Smokers With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Diagnosed schizophrenia schizoaffective disorder Diagnostic Statistical Manual Mental Disorders , Fourth Edition criterion Reported smoke 10 cigarette per day least prior year Expressed desire quit smoke willingness set smoke cessation date within 4 week enrollment Were psychiatrically stable fix dose antipsychotic past 30 day Reported active substance use disorder nicotine caffeine within 6 month enrollment Participants neurologic risk factor bupropion treatment exclude receive bupropion eligible participate receive short longacting NRT CBT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Nicotine Dependence</keyword>
	<keyword>Smoking Cessation</keyword>
	<keyword>Relapse Prevention</keyword>
	<keyword>Cognitive Behavioral Therapy</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>